Celldex Therapeutics ($CLDX) shares plunge ~29% premarket as late-stage barzolvolimab data disappoints

Celldex Therapeutics shares fell about 28.6% premarket after the company reported late-stage trial data for its hives therapy barzolvolimab, reversing the earlier surge tied to Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 results. The stock had jumped sharply when the trials were reported to have met primary and key secondary endpoints at 12 weeks in chronic spontaneous urticaria.

Detected & updated continuously · Source: Nebula